Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Science (New York, N.Y.)|October 27, 2001
Recruitment of Mec1 and Ddc1 checkpoint proteins to double-strand breaks through distinct mechanismsT Kondo, T Wakayama, T Naiki, et al.
The Journal of Infectious Diseases|September 9, 2000
High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitisM Nagaki, H Iwai, T Naiki, et al.
Journal of Hepatology|December 22, 1999
Lethal hepatic apoptosis mediated by tumor necrosis factor receptor, unlike Fas-mediated apoptosis, requires hepatocyte sensitization in miceM Nagaki, A Sugiyama, Y Osawa, et al.
Clinical Radiology|February 7, 2013
MRI findings of granulomatous prostatitis developing after intravesical Bacillus Calmette-Guérin therapyT Suzuki, M Takeuchi, T Naiki, et al.
The American Journal of Gastroenterology|September 14, 1999
Potential utility of magnetic resonance cholangiography in the management of endoscopic biliary drainage tubesT Naiki, Y Shiratori, M Kanematsu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 22, 2001
TNF-alpha-induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytesY Osawa, Y Banno, M Nagaki, et al.
Hepatology (Baltimore, Md.)|November 28, 2000
Tumor necrosis factor alpha prevents tumor necrosis factor receptor-mediated mouse hepatocyte apoptosis, but not fas-mediated apoptosis: role of nuclear factor-kappaBM Nagaki, T Naiki, D A Brenner, et al.
Journal of Gastroenterology|January 5, 2002
Usefulness of MR imaging in the postsurgical monitoring of gallbladder cancer in a patient with bile duct cancer that developed 7 years after resection of mucinous adenocarcinoma of the gallbladderS Takai, Y Shiratori, M Kanematsu, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2009
Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late respondersM Nagaki, M Shimizu, J I Sugihara, et al.
Pageof 2